By IDSE News Staff
The FDA has approved the QuantiFERON-TB Gold Plus (QFT-Plus, QIAGEN) test, the fourth generation of the market-leading blood test for detecting latent tuberculosis infection (LTBI).
With the addition of proprietary CD8+ technology, QFT-Plus has the potential to offer the ability to capture a much broader picture of a person’s immune response to TB infection. This technological advancement is critical to improving the understanding of how the immune system reacts to TB